Brooklyn Story

BTX -  USA Stock  

USD 27.39  3.21  10.49%

It appears Brooklyn Immunotherapeuti will continue to recover much faster as its share price surged up 25.24% today. This firm current daily volatility is 14.06 percent, with a beta of 1.19 and an alpha of 1.1 over DOW. As many millenniums are trying to avoid brooklyn immunotherapeutics, it makes sense to break down Brooklyn Immunotherapeutics a little further and try to understand its current market patterns. We will evaluate why we are still optimistic in anticipation of a recovery.
Published over three weeks ago
View all stories for Brooklyn Immunotherapeuti | View All Stories
Chances of Brooklyn Immunotherapeuti to slide after the volatility rises
Brooklyn Immunotherapeutics has about 3.06 M in cash with (8.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of -0.3074.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Brooklyn Immunotherapeuti has an asset utilization ratio of 3.64 percent. This suggests that the company is making $0.0364 for each dollar of assets. An increasing asset utilization means that Brooklyn Immunotherapeutics is more efficient with each dollar of assets it utilizes for everyday operations.
Investing in Brooklyn Immunotherapeuti, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Brooklyn Immunotherapeuti along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Brooklyn Immunotherapeuti's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Brooklyn Immunotherapeuti in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Brooklyn Immunotherapeuti. Your research has to be compared to or analyzed against Brooklyn Immunotherapeuti's peers to derive any actionable benefits. When done correctly, Brooklyn Immunotherapeuti's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Brooklyn Immunotherapeuti.

How important is Brooklyn Immunotherapeuti's Liquidity

Brooklyn Immunotherapeuti financial leverage refers to using borrowed capital as a funding source to finance Brooklyn Immunotherapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Brooklyn Immunotherapeuti financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Brooklyn Immunotherapeuti's total debt and its cash.

How Brooklyn utilizes its cash?

To perform a cash flow analysis of Brooklyn Immunotherapeuti, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Brooklyn Immunotherapeuti is receiving and how much cash it distributes out in a given period. The Brooklyn Immunotherapeuti cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Brooklyn Immunotherapeuti Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Net Cash Flow from Operations of (3.89 Million) in 2020

Brooklyn Immunotherapeuti Correlation with Peers

Investors in Brooklyn can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Brooklyn Immunotherapeutics. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Brooklyn Immunotherapeuti and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Brooklyn is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of Brooklyn for more details

Acquisition by Federoff Howard J of 597253 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3

Legal trades by Brooklyn Immunotherapeuti insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Brooklyn insider trading alert for grant of stock option by Federoff Howard J, Chief Executive Officer and President, on 20th of April 2021. This event was filed by Brooklyn Immunotherapeuti with SEC on 2021-04-20. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Detailed Perspective On Brooklyn Immunotherapeuti

Brooklyn Immunotherapeuti is dangerous given 1 month investment horizon. Brooklyn Immunotherapeuti secures Sharpe Ratio (or Efficiency) of 0.11, which signifies that the company had 0.11% of return per unit of risk over the last month. Our standpoint towards foreseeing the risk of a stock is to use both market data as well as company specific technical data. We were able to interpolate and analyze data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.59% are justified by taking the suggested risk. Use Brooklyn Immunotherapeuti Downside Deviation of 10.68, risk adjusted performance of 0.0869, and Mean Deviation of 9.49 to evaluate company specific risk that cannot be diversified away.
CSLLY
REGN
NVO
BGNE
ALXN
CSLLY
0.270.590.480.46
CSLLY
REGN
0.270.250.470.76
REGN
NVO
0.590.250.450.44
NVO
BGNE
0.480.470.450.44
BGNE
ALXN
0.460.760.440.44
ALXN
CSLLY
REGN
NVO
BGNE
ALXN
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Over 3 percent rise for Brooklyn Immunotherapeuti. What does it mean for investors?

Current downside variance is at 114.0. Brooklyn Immunotherapeutics is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Brooklyn Immunotherapeuti implied risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Brooklyn Immunotherapeuti's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Brooklyn Immunotherapeuti's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

The Bottom Line

While some other firms within the biotechnology industry are still a little expensive, even after the recent corrections, Brooklyn Immunotherapeuti may offer a potential longer-term growth to investors. To conclude, as of the 17th of April 2021, our ongoing 30 days buy-hold-sell recommendation on the company is Strong Sell. We believe Brooklyn Immunotherapeuti is currently overvalued with close to average odds of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Brooklyn Immunotherapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com